Aptevo Therapeutics Inc. announced executive leadership transitions to support the Company's continued execution, drive achievement of long-term strategic objectives, and next phase of growth. Effective April 1, 2026, Marvin White, who has served as President since 2016, has chosen to retire from this position and assume the role of Executive Chair, where he will focus on cultivating strategic opportunities to help shape long-term success. Jeff Lamothe, currently Chief Operating Officer, will assume the role of President and will join Aptevo's Board of Directors.
John E. Niederhuber, M.D., will transition from Chairman of the Board to Lead Independent Director. All three leaders have been part of Aptevo since the Company's inception in 2016, and the leadership changes reinforce continuity while supporting the Company's continued execution and future success. Under the leadership of Mr. White and Mr. Lamothe, Aptevo has evolved into a company with a clinically validated platform, an expanded and diversified pipeline, and a strong financial foundation.
During their tenure, the Company established proof-of-concept for its proprietary technology, introduced ADAPTIR-FLEX? as a second platform that complements ADAPTIR?, and built a pipeline of eight molecules. Aptevo also broadened its therapeutic scope beyond bispecific antibodies to include two trispecific programs, while creating and executing a strategy to leverage its proprietary and differentiated CD3 binding domain.
The company believe these advances have translated into meaningful clinical outcomes, enabling many patients enrolled in Aptevo's clinical trials to achieve complete remission. More than 100 patients have now been treated with the Company's CD123 x CD3 program, mipletamig, which has demonstrated consistent signals of strong efficacy alongside a differentiated safety profile in acute myeloid leukemia. In parallel, Aptevo has expanded its pipeline through both internal development and external collaboration, including its partnership with Alligator Bioscience for the development of ALG.APV-527 in solid tumors.
Mr. White's move to Executive Chair will deepen Aptevo's focus on harnessing strategic opportunities that align with corporate growth goals and maintaining continuity at the leadership level. As Executive Chair, he will also serve as a strategic advisor, leveraging his experience to help guide Aptevo's next stage of growth. Mr. Lamothe's appointment reflects his central role in Aptevo's accomplishments and his leadership across day-to-day operations and vision for growth.
Many of the Company's key advances-including clinical progress, pipeline development, operational discipline, and financial execution-have occurred under his direct leadership as Chief Operating Officer, in close partnership with Mr. White. In his most recent role as Chief Operating Officer, Mr. Lamothe oversaw Clinical, Research and Development, Quality, Manufacturing, and Operations, strengthening execution across the organization while advancing Aptevo's programs. Previously, as Chief Financial Officer, he led Finance, Business Development, Investor Relations, and Information Technology, providing broad strategic and operational perspective.
